Showing 1 - 10 of 33
Boris Johnson’s first Queen’s Speech delivered on Monday 14 October 2019 - dominated by Brexit-related legislation - included the Medicines and Medical Devices Bill (the Bill).
Our product liability and life sciences team recently hosted their fifth life sciences conference which focused on emerging risks in innovative healthcare technology.
Lab-grown meat is not just the latest product for environmentally conscious consumers, it also heralds a new type of agriculture and food product design, which could offer attractive risk profiles for insurers that get to know the science.
Case review 14/11/2019
In Bailey & Ors v GlaxoSmithKline “The Seroxat Group Litigation” [08.11.19] the Court of Appeal decided that it was impermissible for the claimants to expand the scope of their pleaded case at trial, which was previously determined at both the case management stage and during the pre-trial review.
A roundup of recent cyber related developments including: non-material damages under the GDPR; data protection laws in Asia-Pacific; cyber attacks in the education sector; regulation of cryptoassets; blockchain in the pharmaceutical industry; challenges presented by autonomous vehicles; and algorithms as a new emerging risk.
With the current Article 50 extension deadline of 31 October 2019 looming against a complex and uncertain political backdrop, and talks between the UK and EU continuing without any clear sign of a definitive outcome, the possibility of a no-deal Brexit remains at an all-time high.
Following today's Queen's Speech, we have officially responded to some key domestic legislation relating Air Traffic Management and Unmanned Aircraft Bill, and the Medicines and Medical Devices Bill.
In a week that is likely to be dominated by ongoing Brexit negotiations and timelines, we have today been provided with this Government’s priorities and legislative programme in the Queen’s Speech which took place this morning.
IBM recently announced its latest blockchain initiative in partnership with KPMG, Merck and Walmart. The consortium’s goal is to develop a pharmaceutical blockchain platform that can track drugs as they move through the global supply chain, from manufacturer to end user.
We are pleased to announce that we have grown our presence in Portugal by merging with boutique Portuguese firm N. Maldonado Sousa & Associados. The merged firm will move into our existing Lisbon office in the centre of the city.
A roundup of recent cyber related developments, including the black box effect in ship risk profiling, GDPR fines from the ICO, silent cyber risks, cyber threats to the life sciences sector, insuring the emerging offshore digital assets industry and claims transformation in Latin America.